Enveric Biosciences to Participate in Upcoming Investor Conferences in March 2022

Enveric Biosciences (NASDAQ: ENVB) announced CEO Dr. Joseph Tucker's participation in three investor conferences in March 2022.

Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) announced CEO Dr. Joseph Tucker's participation in three investor conferences in March 2022. The events include the Q1 Virtual Investor Summit on March 8 at 11:45 a.m. ET, Citi's Psychedelic Drug Call Series on March 10 at 10:00 a.m. ET, and the Maxim 2022 Virtual Growth Conference from March 28-30. Attendees can register online for each conference. Enveric focuses on developing psychedelic-inspired mental health medicines to aid patients suffering from conditions like cancer-related distress and PTSD.

Argus Session date unavailable

+0.84% session move Open Argus

Details

News Market Reaction – ENVB

The recorded move for ENVB in the trading session of this news was +0.84%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NAPLES, Fla., March 3, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a cutting-edge neuroscience company developing next-generation, psychedelic-inspired mental health medicines, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in three upcoming investor conferences:

Q1 Virtual Investor Summit
Tuesday, March 8^th at 11:45 a.m. ET
To attend, please register here.

Citi's Psychedelic Drug Call Series
Thursday, March 10^th at 10:00 a.m. ET
A fireside chat hosted by Neena Bitritto-Garg, Citi's Biotech analyst.

Maxim 2022 Virtual Growth Conference
Monday, March 28^th – Wednesday, March 30^th
To attend, please register here.

For more information about the events, or to schedule a one-on-one meeting with Enveric's management team, please contact your appropriate Investor Summit Group, Citi, or Maxim representative, respectively, or send an email to KCSA Strategic Communications at EnvericBio@kcsa.com.

About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a neuroscience-focused pharmaceutical company developing next-generation, psychedelic-inspired mental health medicines. Enveric's robust pipeline supports drug development from the clinic to commercialization aimed to help millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For additional information, please visit www.enveric.com.

View original content:https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-upcoming-investor-conferences-in-march-2022-301494565.html

SOURCE Enveric Biosciences

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What dates will Enveric Biosciences participate in investor conferences?

Enveric Biosciences will participate in three investor conferences on March 8, March 10, and from March 28 to March 30, 2022.

Who is presenting for Enveric Biosciences at the investor conferences?

Dr. Joseph Tucker, CEO of Enveric Biosciences, will present at the investor conferences.

Where can I register for the Enveric Biosciences investor conferences?

You can register for the conferences through the links provided in the press release.

What is Enveric Biosciences' focus in the pharmaceutical industry?

Enveric Biosciences focuses on developing next-generation, psychedelic-inspired mental health medicines.

What conditions does Enveric Biosciences aim to treat?

Enveric Biosciences aims to treat conditions such as cancer-related distress and PTSD.